135 related articles for article (PubMed ID: 15602006)
1. Biochemical and proteomics approaches to characterize topoisomerase IIalpha cysteines and DNA as targets responsible for cisplatin-induced inhibition of topoisomerase IIalpha.
Hasinoff BB; Wu X; Krokhin OV; Ens W; Standing KG; Nitiss JL; Sivaram T; Giorgianni A; Yang S; Jiang Y; Yalowich JC
Mol Pharmacol; 2005 Mar; 67(3):937-47. PubMed ID: 15602006
[TBL] [Abstract][Full Text] [Related]
2. Thiol-modulated mechanisms of the cytotoxicity of thimerosal and inhibition of DNA topoisomerase II alpha.
Wu X; Liang H; O'Hara KA; Yalowich JC; Hasinoff BB
Chem Res Toxicol; 2008 Feb; 21(2):483-93. PubMed ID: 18197631
[TBL] [Abstract][Full Text] [Related]
3. A three-dimensional quantitative structure-activity analysis of a new class of bisphenol topoisomerase IIalpha inhibitors.
Liang H; Wu X; Yalowich JC; Hasinoff BB
Mol Pharmacol; 2008 Mar; 73(3):686-96. PubMed ID: 18045852
[TBL] [Abstract][Full Text] [Related]
4. A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIalpha by substituted purine analogs.
Jensen LH; Liang H; Shoemaker R; Grauslund M; Sehested M; Hasinoff BB
Mol Pharmacol; 2006 Nov; 70(5):1503-13. PubMed ID: 16880287
[TBL] [Abstract][Full Text] [Related]
5. Substituted purine analogues define a novel structural class of catalytic topoisomerase II inhibitors.
Jensen LH; Thougaard AV; Grauslund M; Søkilde B; Carstensen EV; Dvinge HK; Scudiero DA; Jensen PB; Shoemaker RH; Sehested M
Cancer Res; 2005 Aug; 65(16):7470-7. PubMed ID: 16103101
[TBL] [Abstract][Full Text] [Related]
6. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
Khélifa T; René B; Le Mée S; Lambert B; Saucier JM; Markovits J; Jacquemin-Sablon H; Jacquemin-Sablon A
Cancer Res; 1999 Oct; 59(19):4927-36. PubMed ID: 10519406
[TBL] [Abstract][Full Text] [Related]
7. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
Chen S; Gomez SP; McCarley D; Mainwaring MG
Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828
[TBL] [Abstract][Full Text] [Related]
8. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
Matsumoto Y; Takano H; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
[TBL] [Abstract][Full Text] [Related]
9. Kinamycins A and C, bacterial metabolites that contain an unusual diazo group, as potential new anticancer agents: antiproliferative and cell cycle effects.
Hasinoff BB; Wu X; Yalowich JC; Goodfellow V; Laufer RS; Adedayo O; Dmitrienko GI
Anticancer Drugs; 2006 Aug; 17(7):825-37. PubMed ID: 16926632
[TBL] [Abstract][Full Text] [Related]
10. Topoisomerase IIalpha inhibition following DNA transfection greatly enhances random integration in a human pre-B lymphocyte cell line.
Toyoda E; Kurosawa A; Kamekawa H; Adachi N
Biochem Biophys Res Commun; 2009 May; 382(3):492-6. PubMed ID: 19285952
[TBL] [Abstract][Full Text] [Related]
11. Salvicine functions as novel topoisomerase II poison by binding to ATP pocket.
Hu CX; Zuo ZL; Xiong B; Ma JG; Geng MY; Lin LP; Jiang HL; Ding J
Mol Pharmacol; 2006 Nov; 70(5):1593-601. PubMed ID: 16914642
[TBL] [Abstract][Full Text] [Related]
12. Analysis of inhibition of topoisomerase IIalpha and cancer cell proliferation by ingenolEZ.
Yoshida C; Hishiyama K; Miyazaki K; Watanabe M; Kanbe M; Yamada Y; Matsuzaki K; Miyashita K; Kitanaka S; Miyata S
Cancer Sci; 2010 Feb; 101(2):374-8. PubMed ID: 20175785
[TBL] [Abstract][Full Text] [Related]
13. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human and mouse breast cancer cells.
Asano T; Kleinerman ES; Zwelling LA; Zhou Z; Fukunaga Y
Acta Oncol; 2005; 44(3):240-7. PubMed ID: 16076696
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of DNA topoisomerase IIalpha leads to prolonged cell cycle transit in G2 and early M phases and increased survival to microtubule-interacting agents.
Skladanowski A; Côme MG; Sabisz M; Escargueil AE; Larsen AK
Mol Pharmacol; 2005 Sep; 68(3):625-34. PubMed ID: 15942022
[TBL] [Abstract][Full Text] [Related]
15. Quinolone action against human topoisomerase IIalpha: stimulation of enzyme-mediated double-stranded DNA cleavage.
Bromberg KD; Burgin AB; Osheroff N
Biochemistry; 2003 Apr; 42(12):3393-8. PubMed ID: 12653542
[TBL] [Abstract][Full Text] [Related]
16. Activation of the unfolded protein response is necessary and sufficient for reducing topoisomerase IIalpha protein levels and decreasing sensitivity to topoisomerase-targeted drugs.
Gray MD; Mann M; Nitiss JL; Hendershot LM
Mol Pharmacol; 2005 Dec; 68(6):1699-707. PubMed ID: 16141312
[TBL] [Abstract][Full Text] [Related]
17. E1A specifically enhances sensitivity to topoisomerase IIalpha targeting anticancer drug by up-regulating the promoter activity.
Zhou Z; Guan H; Kleinerman ES
Mol Cancer Res; 2005 May; 3(5):271-5. PubMed ID: 15886298
[TBL] [Abstract][Full Text] [Related]
18. Increased topoisomerase IIalpha expression in colorectal cancer is associated with advanced disease and chemotherapeutic resistance via inhibition of apoptosis.
Coss A; Tosetto M; Fox EJ; Sapetto-Rebow B; Gorman S; Kennedy BN; Lloyd AT; Hyland JM; O'Donoghue DP; Sheahan K; Leahy DT; Mulcahy HE; O'Sullivan JN
Cancer Lett; 2009 Apr; 276(2):228-38. PubMed ID: 19111388
[TBL] [Abstract][Full Text] [Related]
19. Anti-DNA topoisomerase IIalpha autoantibodies in localized scleroderma.
Hayakawa I; Hasegawa M; Takehara K; Sato S
Arthritis Rheum; 2004 Jan; 50(1):227-32. PubMed ID: 14730620
[TBL] [Abstract][Full Text] [Related]
20. C-terminal regions of topoisomerase IIalpha and IIbeta determine isoform-specific functioning of the enzymes in vivo.
Linka RM; Porter AC; Volkov A; Mielke C; Boege F; Christensen MO
Nucleic Acids Res; 2007; 35(11):3810-22. PubMed ID: 17526531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]